

Immune history influences SARS-CoV-2 booster impacts: the role of efficacy and redundancy

Sophie L. Larsen¹, Iffat Noor², Haylee West³, Eliana Chandra^{4,5}, Pamela P. Martinez^{3,5,6*}, and Alicia N. M. Kraay^{2,6*}

¹*Program in Ecology, Evolution, and Conservation Biology, School of Integrative Biology, University of Illinois Urbana-Champaign, Urbana, IL, USA*

²*Department of Kinesiology and Community Health, University of Illinois Urbana-Champaign, Champaign, IL, USA*

³*Department of Microbiology, School of Molecular and Cellular Biology, University of Illinois Urbana-Champaign, Urbana, IL, USA*

⁴*Department of Sociology, University of Illinois Urbana-Champaign, Champaign, IL, USA*

⁵*Department of Statistics, University of Illinois Urbana-Champaign, Urbana, IL, USA*

⁶*Carl R. Woese Institute for Genomic Biology, University of Illinois Urbana-Champaign, Urbana, IL, USA*

Abstract

Given the continued emergence of SARS-CoV-2 variants of concern as well as unprecedented vaccine development, it is crucial to understand the effect of the updated vaccine formulations at the population level. While bivalent formulations have higher efficacy in vaccine trials, translating these findings to real-world effectiveness is challenging due to the diversity in immune history, especially in settings with a high degree of natural immunity. Known socioeconomic disparities in key metrics such as vaccine coverage, social distancing, and access to healthcare have likely shaped the development and distribution of this immune landscape. Yet little has been done to investigate the impact of booster formulation in the context of host heterogeneity. Using two complementary mathematical models that capture host demographics and immune histories over time, we investigated the potential impacts of bivalent and monovalent boosters in low- and middle-income countries (LMICs). These models allowed us to test the role of natural immunity and cross-protection in determining the optimal booster strategy. Our results show that to avert deaths from a new variant in populations with high immune history, it is more important that a booster is implemented than which booster is implemented (bivalent vs. monovalent). However, in populations with low preexisting immunity, bivalent boosters can become optimal. These findings suggest that for many LMICs - where acquiring a new vaccine stock may be economically prohibitive - monovalent boosters can still be implemented as long as pre-existing immunity is high.

* To whom correspondence should be addressed: pamelapm@illinois.edu and alicia.kraay@gatesfoundation.org

Introduction

Host and pathogen heterogeneity are at the core of understanding infectious disease dynamics, including the potential benefit of intervention strategies like the original SARS-CoV-2 monovalent and updated bivalent booster vaccines. At the individual level, variation in behavior, viral shedding, and/or infectiousness can drive superspreading events across pathogens (e.g. [1, 2]). At the population level, host factors can also influence disease transmission. For instance, rent-to-income ratio and population density are associated

38 with SARS-CoV-2 superspreading in Hong Kong, a so-called “double disadvantage” for impoverished indi-
39 viduals living in high-risk urban residential environments [3]. Lockdown mobility, testing, vaccination, and
40 mortality during the SARS-CoV-2 pandemic have all been shown to be associated with socioeconomic status
41 (SES) [4–6]. Beyond the host, some pathogens evolve over time, with broad impacts on transmission poten-
42 tial. Rapid evolution observed for SARS-CoV-2 resulted in the emergence of several variants distinct from
43 the original wild-type virus, including Omicron. One early-pandemic estimate of the household secondary
44 attack rate for SARS-CoV-2 was placed at 18.9%, but later rose to 42.7% for Omicron cases [7].

45 It is crucial to understand the interactions of these pathogen and host factors cumulatively, through time. As
46 historical variants give way to their successors, experimental work with serological data has documented
47 substantial differences in immune response to SARS-CoV-2 variants and vaccination by variant-specific
48 immune history (e.g. [8–10]). This suggests the presence of an immune imprinting effect, where an individ-
49 ual’s prior exposure can impact the adaptive immune response to new infections [8, 11] - a phenomenon not
50 only observed for SARS-CoV-2, but also in other respiratory viruses such as influenza and SARS-CoV-1
51 (e.g. [12, 13]). This signature is also present in mouse models when immunizing sequentially with SARS-
52 CoV-2 and SARS-CoV-1 or endemic coronaviruses [14, 15]. Despite these serological findings, the impacts
53 of SARS-CoV-2 imprinting at the population level are presently unknown. Given that host factors are known
54 to have influenced transmission dynamics and protective behaviors throughout the pandemic ([3–5]), they
55 also have the potential to shape variant history and the development of the immune landscape of the popu-
56 lation. For example, an individual with low SES who was not able to social distance early in the pandemic
57 [4] might be more likely to have had an early-pandemic infection prior to the emergence of new variants.
58 On the other hand, a low SES individual is less likely to be vaccinated than a high SES counterpart [5].
59 Yet socioeconomic status is still a commonly unrecognized axis of host heterogeneity in disease modeling
60 [16, 17].

61 Mathematical models can be wielded as a powerful tool for public health when host- and pathogen-level
62 data are plentiful, but an understanding of complex population-level dynamics is lacking [18]. Understand-
63 ing booster impacts under the influence of population and pathogen heterogeneity can inform not only the
64 acquisition and implementation of booster vaccines but also shed light on future strategies for booster formu-
65 lation. In this work, we synthesized serological measures of variant-specific immune history, socioeconomic
66 disparities, temporal vaccination trends, and broad variation of historical variant wave sizes to inform mod-
67 els of transmission for three countries (India, Ecuador, and Malaysia) and evaluated possible landscapes of
68 immunity more broadly across low- and middle-income country (LMIC) settings. Using this immune his-
69 tory, we forward-simulated the potential impacts of three formulations of bivalent or monovalent boosters
70 in two models with complementary strengths, in the context of diverse landscapes of immunity and varying
71 levels of pathogen immune escape or adaptation in infectiousness.

72 **Results**

73 **Landscape of immunity**

74 In order to characterize the effect of variant-specific immunity on population-level booster impact, we iden-
75 tified three discrete, historical waves of SARS-CoV-2 for our analysis - Wild-type (WT), Delta, and Omicron
76 - using India, Ecuador, and Malaysia as benchmark countries due to the diverse sizes of their variant waves
77 (Figure S1). We first implemented a model that tracks the variant-specific immune history of individuals
78 at each time-point, captures relative wave size for each country (Figure S2, Table S1), and incorporates the

79 observed temporal vaccination trends for each country and socioeconomic group (Figure S3, Table S2). We
 80 refer to this as the history-specific model or HSM, and under this model, an individual's risks of infection
 81 are explicitly influenced by their specific immune history and the currently circulating variant, while the
 82 infection fatality rate is influenced by immune history, socioeconomic status, and age (Figure 1A, Table S3).

83 Using the variant-specific immune histories of individuals tracked through historical simulations in the
 84 HSM, we explored the possible immune landscapes over time for the three countries prior to a booster
 85 intervention (Figure 1B) and inferred the prevalence of each history type prior to the time of boosting at
 86 28 months (Figure S4). Our findings suggest that India had the highest share of naive individuals, with
 87 an average of 7.8% of the population having never been infected or vaccinated. Their vaccine-only pop-
 88 ulation was also high (40.9%) compared to Ecuador (23.1%) and Malaysia (10.9%). Yet, despite having
 89 lower natural exposure overall, our simulations indicate that India carried by far the highest percentage of
 90 'Delta' and 'Delta + vaccine' histories, at values of 5.6% and 19.4% respectively. In Malaysia, 'Delta'
 91 exposures appeared to be less common, but there was a much higher presence of 'Omicron' histories than
 92 in India (3.0% for 'Omicron' and 24.3% for 'Omicron + vaccine'). A pattern similar to that of Malaysia
 93 was present in Ecuador, where Omicron histories were also more prevalent than Delta or WT. We used
 94 these diverse immune histories, particularly in comparing vaccine-only versus hybrid immunity, to assess
 95 the population-level of protection from a booster intervention under varying hypotheses of individual-level
 96 efficacy.

97 Impact of booster formulation on disease incidence and deaths

98 We introduced booster vaccines at 28 months under three formulations - bivalent (WT + Omicron), mono-
 99 valent (WT), and a hypothetical monovalent (Omicron) - and considered two possible scenarios of pathogen
 100 infectiousness (Table S3): one that is conservative (110% relative to Omicron) and another that more closely
 101 resembles previous increases in the observed secondary attack rate (SAR) between variants (130% relative




Figure 1: Landscapes of immunity from the history-specific model (HSM). (A) Level of protection from severe disease by immune history and variant wave, estimated using neutralizing antibody titers in human sera [19, 20]. Lengths 2, 3, and 4+ represent permutations of immune history that were not explicitly tracked (e.g. 'WT + Delta + Omicron'). (B) Average immune history trajectories of 500 runs informed by historical incidence data from Ecuador, India, and Malaysia shown in Figure S1 [21]. Simulations of the prevalence of histories are shown until day 839, one day before booster vaccinations are implemented at 28 months. The infections over time for each country are shown in Figure S2. General simulation parameters are shown in Table S3, with country-specific population structure in Table S4, contact rates by country and SES in Table S5, wave- and country-specific stringency in Table S1, and vaccination parameters by country and SES in Table S2. The HSM compartmental diagram is shown in Figure S5.

102 to Omicron), considering that the SAR for Delta was $\sim 60\%$ higher than early-pandemic estimates and the
103 SAR for Omicron was $\sim 40\%$ higher than for Delta [7]. To model protection conferred by these boosters,
104 we considered a ‘history-dependent’ scenario where the impact of each formulation is based on an indi-
105 vidual’s prior exposure, and calculated relative to history-specific responses to primary series vaccination
106 (Figure S6). At 30 months, we introduced the Omicron* variant and updated history-specific immunity for
107 both boosted and unboosted individuals (Figures 1A, 2A). Unsurprisingly, our results show that boosting
108 always reduced cases (Figure 2B) and disease-related deaths (Figure 2C) in all three countries during this
109 new wave, regardless of formulation. For example, in the 130% infectiousness scenario, wave peaks with
110 boosting were 22-37% lower than the peak with no boosting in India, 33-39% in Ecuador, and 44-45% in
111 Malaysia. The smaller reduction observed in India may be attributable to a lower boosting rate (Figure S3)
112 and the distinct immune landscape compared to Malaysia and Ecuador (Figure 1B).

113 In order to quantify the difference in deaths averted during the Omicron* wave across booster formulations
114 (Figure 2C), we estimated the relative benefit of switching from monovalent (WT) to monovalent (Omicron)
115 or to bivalent (Equation 1) specific to each country and scenario. Values < 1 represent a net loss in deaths
116 averted from changing booster formulations, whereas values > 1 represent that the new formulation averts
117 more deaths than the previous formulation. If the benefit of switching from monovalent (WT) to a different
118 formulation is greater than the original benefit of implementing the monovalent (WT), then the relative ben-
119 efit will be greater than 2. Therefore, if the relative benefit is in the interval $(1, 2)$, then the new formulation
120 is still optimal to the monovalent (WT) booster in the given scenario, but the effect of boosting on the deaths
121 averted is stronger than the effect of booster formulation.

122 When comparing the relative benefit of switching to monovalent (Omicron), India was the only country
123 that would slightly benefit from this hypothetical booster, represented by values greater than 1.0 in both the
124 110% and 130% more infectious scenarios (Table S6). This marginal benefit in India may be attributable to
125 the high prevalence of Omicron histories in Ecuador and Malaysia compared to India, where Delta histories
126 appeared to be more prevalent (Figure 1B). When looking at the case of bivalent boosters, we found that
127 in the 110% infectiousness scenario, the relative benefit of bivalent boosters was 1.12, 1.18, and 1.66, for
128 Malaysia, Ecuador, and India, respectively. For the 130% infectiousness scenario, the relative benefit of
129 bivalent boosters was 1.09 for Malaysia, 1.12 for Ecuador, and 1.77 for India (Table S6).

130 This surprising finding - that switching formulations from monovalent (WT) to bivalent in a given sce-
131 nario always yielded diminishing returns on the deaths averted with relative benefit values less than 2.0 -
132 was consistent even in scenarios with conservative booster rollout speed (Figures S3E, S7, Table S7), and
133 in scenarios where booster curves for all countries match the superior rollout trajectory seen in Malaysia
134 (Figure S8, Table S7). In order to isolate the effects of the boosters, the main results show findings when
135 primary-series vaccination is stopped at the end of the Omicron wave. When we relaxed this assumption
136 by continuing primary series vaccination through Omicron*, we found that this did not cause the relative
137 benefit of the bivalent to surpass 2.0 (Figures S3C, S9, Table S7). Finally, while our history-specific booster
138 scenarios were informed by responses to primary series vaccination, they were hypothetical. We therefore
139 tested two additional scenarios for booster efficacy: (1) same efficacy, where all individuals received the
140 same numeric change in protection from a given booster (Figure S10), and (2) same endpoint, where all
141 individuals reached the same end level of protection from boosting (Figure S11). The conclusion about the
142 relative benefit of bivalent boosters remained consistent (Table S7).




Figure 2: HSM booster parameters and projections during the Omicron* period. (A) Booster protection against severe disease during the Omicron* wave, by immune history, under a bivalent, WT monovalent, or hypothetical Omicron monovalent formulation. (B) Infection trends under three boosters or a no-boosting scenario based on the characteristics of Ecuador, India, and Malaysia. We simulated two scenarios of infectiousness where Omicron* is 10% or 30% more infectious than Omicron. 95% confidence intervals from the t-distribution are shown (ribbons). (C) Deaths averted by boosting since the start of Omicron* (30 months) through the end of simulations, under each booster. 95% confidence intervals from the t-distribution are shown with whiskers. Boosting parameters, which are assumed to be 10 weeks faster than for primary series vaccination, are shown in Table S8.


143 Beyond country-specific trajectories

144 In order to explore a wider range of scenarios that capture the relative influence of preexisting immunity
 145 and degree of overlap with the currently circulating variant, we implemented a complementary and flexible
 146 model, which we call the hybrid-immunity model (HIM). The HIM is a compartmental model that tracks
 147 prior infection (none, one or more; not variant-specific), vaccine history (none, primary series, primary
 148 series+booster), and simulates expected cases and deaths during the Omicron* wave. For the three bench-
 149 marking countries, the level of cross-protection, prior infection, and baseline transmission rates expected are
 150 parameterized based on the outputs of the history-specific model prior to boosting (Figures 1B, S4, Table
 151 S1, S9). Country-specific booster trends are also matched (Figure S12). This allowed us to compare the
 152 predictions between the two models for the benchmarked countries. We then used the hybrid immunity
 153 model to vary these dimensions of immunity and to more thoroughly explore how booster impacts might
 154 be influenced by prior population infection and the degree of cross protection conferred by natural infec-
 155 tion. To determine prior infections and cross protection at the start of the HIM simulations on day 900, we
 156 used immune history distributions from day 899 in the HSM under a no-boosting scenario (Figure S13);
 157 these may overestimate the cross protection, but because there is limited booster impact on the number of
 158 infections during the window from day 839 to 899 (Figure S2), this is a close approximation.

159 In general, projections of infections during Omicron* for the three countries were qualitatively similar for the
 160 HIM compared with the HSM, with similar outbreaks (Figure 3A). For the 110% infectiousness scenario,

161 the HIM predicted small outbreaks in the three countries. All three countries experienced outbreaks in the
 162 130% infectiousness scenario, with the biggest peaks in Malaysia and India. Boosting reduced the size of the
 163 Omicron* wave across all three countries, with bivalent boosters having a stronger impact than monovalent
 164 boosters. However, similar to the HSM, the impact of vaccine formulation was small. When looking at
 165 deaths across the three countries, models revealed substantial differences across countries in the potential for
 166 booster impacts, with India having by far the highest number of deaths with or without boosting, matching
 167 the HSM (Figures S14, S15). This split in deaths across countries was larger overall in the HIM than in the
 168 HSM, and additionally, the HIM predicted smaller outbreaks for Malaysia than the HSM. As a result India
 169 was predicted to have the strongest potential benefit of boosting on deaths averted per 10,000 (Figures 3B
 170 (black dots), S16, Table S11). Like the HSM, these findings from the HIM were similar in the conservative
 171 booster rollout case (Figures S16, S17), but overall deaths were higher with slower booster rollout (Figure
 172 S14). We also tested scenarios where boosting started at the beginning of the Omicron* wave (Figure S18),
 173 with similar findings but lower deaths averted overall (Figures S19, S20).

A Infections during Omicron* – Hybrid immunity model



B Deaths averted – Hybrid immunity model




Figure 3: HIM projections. (A) Infections per 10,000 during the Omicron* period, where Omicron* is considered to be 10% or 30% more infectious than Omicron. (B) Deaths averted per 10,000 under a bivalent or monovalent booster, compared to a ‘no boosting’ scenario. Prior immunity represents the percentage of the population that has been previously infected. Cross protection represents the overlap between the population’s immune history and the currently circulating variant. Country-specific immunity levels are included (black dots). The HIM model structure is shown in Figure S5. General parameters are shown in Table S3, stringency in Table S1, initial conditions in Table S10, cross-protection in Table S9, and boosting parameters in Table S8.

174 Consequences of immune escape and cross protection in diverse immunity contexts

175 Broader sweeps across the immune landscape using the HIM revealed that the similarity between monova-
176 lent and bivalent booster performance was largely determined by population immunity (Figure 3B, Figure 4).
177 Generally, the gains from implementing a bivalent booster were most pronounced at low levels of popula-
178 tion immunity, but absolute differences remained relatively small for all parameter values considered. The
179 difference between monovalent and bivalent vaccination was smallest at high levels of cross protection and
180 prior exposure (as was seen in the three benchmarking countries), and diverged more as the protection from
181 natural infection decreased across both dimensions. For example, in Malaysia, the HSM estimated that
182 90.7% of the population had been infected by the start of Omicron* and that this protection conferred a
183 72.8% protection against disease-related death (Table S9). At that preexisting immunity level in a 130%
184 infectiousness scenario, monovalent boosting was expected to avert 0.14 deaths per 10,000 compared with
185 0.22 deaths per 10,000 in the bivalent vaccination scenario, representing that the additional gain in deaths
186 averted from jumping to an improved formulation (0.08) is just over half of what was gained when mov-
187 ing from no-boosting to monovalent - a relative benefit of 1.57 (Equation 1, Figure 4). These diminishing
188 returns account for much of the high-immunity parameter space. However, in the absence of any baseline
189 immunity, bivalent boosting could avert 3.4 deaths per 10,000 compared with 0.6 deaths per 10,000 in the
190 monovalent case. This gain of 2.8 deaths averted per 10,000 by improving formulations, compared to 0.6
191 gained by simply boosting, represents a relative benefit of 5.67. In the other countries, diminishing returns
192 accounted for a wider swath of the parameter space (Figure 4). In general, at hypothetical lower levels of
193 immunity, Malaysia was predicted to have higher impacts than the other countries (Figure 3B), reflecting
194 that booster curves for Malaysia were superior (Figure S12). Whereas the total deaths averted were similarly
195 sensitive to both the cross protection and prior infections (Figure 3B), the prevalence of prior infection was




Figure 4: Comparison of bivalent vs. monovalent boosters in the HIM. Relative benefit of the bivalent booster is calculated with Equation 1, matching the HSM. Grey values represent high-immunity areas where zero deaths were averted by a monovalent booster and thus Equation 1 cannot be calculated. Prior immunity represents the percentage of the population that has been previously infected. Cross protection represents the overlap between the population's immune history and the currently circulating variant. Country-specific immunity levels are included (black dots).

Country	SAR	Booster	Match HSM	Adjust Transmission	Transmission Recalibrated
Ecuador	110%	Monovalent	0.07	0.3	0.57
	110%	Bivalent	0.11	0.94	0.84
	130%	Monovalent	0.27	0.24	0.59
	130%	Bivalent	0.38	0.88	1.02
India	110%	Monovalent	0.4	0.13	0.67
	110%	Bivalent	0.57	0.61	1.14
	130%	Monovalent	0.58	0.1	0.43
	130%	Bivalent	0.96	0.58	0.9
Malaysia	110%	Monovalent	0.06	0.32	0.45
	110%	Bivalent	0.11	1	0.6
	130%	Monovalent	0.14	0.28	0.57
	130%	Bivalent	0.22	1	0.86

Table 1: Comparison of HIM deaths per 10,000 across three scenarios: (1) Matching the HSM (column 4; as shown in Figures 3 and 4) (2) Removing the reduction in transmission for people with pre-existing immunity (column 5), and (3) Removing the transmission reduction but recalibrating β to remain consistent with Omicron [23] (column 6).

196 the greatest determining factor in whether a bivalent booster would be optimal.

197 The HSM and HIM both assumed that individuals with pre-existing immunity have strongly reduced infec-
 198 tiousness based on [22], but this may not always be the case, particularly as new variants emerge. We thus
 199 tested an additional scenario in the hybrid immunity model where prior exposure or immunization had no
 200 impact on host infectiousness during the Omicron* wave, under two parameterizations. First, we left all
 201 other parameters related to the force of infection unchanged, including the baseline risk of infection given
 202 contact, but removed all transmission-reducing effects during Omicron* so that the effective infectious pro-
 203 portion is equal to the total infectious proportion. In this extreme scenario, all three countries experienced
 204 large waves regardless of whether the baseline infectiousness for Omicron* was 10% or 30% greater than
 205 Omicron (Figure S21). Under these conditions, it was almost always optimal to implement a bivalent booster
 206 (Figure S22). However, stringency in the HSM and HIM was calibrated to observed wave sizes for Omicron
 207 *with* the assumption of transmission-reducing immunity, so this scenario represents an extreme jump in the
 208 overall force of infection. We therefore ran an additional analysis where the overall force of infection was
 209 re-calibrated to fit the R_0 of Omicron (Table S3) without transmission-reducing effects (Figures S23, S24).
 210 In this scenario, cases were still increased but the relative benefit of bivalent boosting was less than 2.0
 211 in most of the high-immunity parameter space, and in all but one country-specific scenario (India, 130%
 212 more infectious). In general, HIM-projected deaths tended to be lower than the HSM across sensitivity
 213 analyses (Figures S14, S25, S26) - except in the case where transmission structure was adjusted but β was
 214 not recalibrated (Figure S27) - reflecting differences in the structure of immunity; the HSM is designed to
 215 capture more complex dynamics of immunity over time, number, and type of exposures, whereas the HIM
 216 tracks recent recovery (sterilizing immunity) and tiers of susceptibility depending on vaccination status and
 217 infection-naïve versus previously infected. This was also reflected in the scale of the deaths averted which
 218 were generally lower across scenarios (Table 1).

219 Finally, in the HIM, we assume that 50% of individuals with prior infection start in the recovered (R)
 220 compartment due to the short interval between transmission waves. The remainder start in the susceptible
 221 but previously infected compartment. This assumption is roughly consistent with most of current population

immunity having been gained during the Omicron wave (like in Malaysia and Ecuador), of which roughly half would have waned at the start of the Omicron* wave. Thus, at very high levels of prior immunity, a substantial fraction of the population cannot be reinfected until waning occurs, which could influence our estimates of booster impact. Additionally, this assumption may be less realistic for India, which experienced a larger Delta wave than Omicron (Figures S1, S2). As a sensitivity analysis, we re-ran our model assuming that only 25% of individuals with prior infection start in the R compartment. While cases and deaths were higher (Figures S28A, S29), the overall findings were unchanged (Figures S28, S30).

Discussion

The continued emergence of new variants of SARS-CoV-2 poses a challenge for maintaining effective vaccine-induced immunity in the population. As individuals continue to acquire diverse immune histories that confer highly varied protection against newer variants [8], understanding the impact of old and new vaccine formulations in populations with varying exposure histories is crucial. We found that at the population level, particularly in the current context where population immunity is high, it is more important that a booster is implemented, than whether that booster is bivalent or monovalent. Strikingly, this was largely consistent across all three countries in both models, even in scenarios where rollout speed was conservative or an emerging variant was highly transmissible. While bivalent boosters showed a greater benefit when the rate of previous SARS-CoV-2 infections was low, those scenarios are unlikely for most countries. For example, a meta-analysis found that the rate of infection-induced seroprevalence in India may have been higher than 50% by the third quarter of 2021 [24], a year before bivalent boosters became available. In Malaysia, estimates from reported cases and age-stratified case fatality rates suggest that approximately 33% of individuals had been infected by December 2021, with only 23% of cases estimated to be reported [25]. Infection-induced seroprevalence estimates for a selection of European low- and middle-income countries (LMICs) had surpassed 50% by as early as November 2020 [24]. The continued benefit of the original monovalent boosters in these contexts is an encouraging finding, especially given that it may not be economically viable for an LMIC to acquire an entirely new vaccine stock. Still, care should be taken in interpreting the effect size of formulation across countries with varying population sizes, since 1 death averted per 10,000 is a larger absolute number in India than in Ecuador. Policymakers should consider the balance between relative and absolute gains when deciding which formulation to implement.

Monovalent boosters targeting the most recently circulating variant did not perform better than WT monovalent formulations in populations with a high degree of natural exposure. Red Queen dynamics [26] as well as documented imprinting effects [8] may give rise to an endless race to capture the newest variant match. While exploring boosters that directly target emerging variants is beyond the scope of this study, this has been the case for influenza virus. Influenza vaccine development and strain selection are based on what might be circulating during the upcoming season - informed by predictive models [27, 28] - and there can be severe impacts on vaccine efficacy if expectations do not align with reality [27]. In the face of this, a possible future direction for SARS-CoV-2 to make population-level gains in immunity is the development of pan-sarbecovirus or pan-coronavirus vaccines that induce broad cross-reactivity [29, 30]. Indeed, experimental work is already underway that supports this goal, but with a potentially long road ahead [29, 30].

Several additional factors should be considered when interpreting the findings of this paper. First, this work was conducted in response to a call from the World Health Organization in August 2022, and therefore our models and assumptions were built between 2022 and 2023. During a new variant wave, assumptions on the force of infection, rate of booster uptake, level of immune escape, and other factors are exploratory and

264 hypothetical. We acknowledge that our simulations of Omicron* may be different from currently circulating
265 variants and newly available boosters, but exploring post-Omicron lineages is beyond the scope of this
266 study. Second, while neutralizing antibody titers allowed us to parameterize variant-specific protection in
267 a way that could not be done with existing clinical trial data, and correlation with protection has been
268 previously suggested for SARS-CoV-2 [31], we acknowledge that titers may not always be a good correlate
269 of protection in all cases (e.g. [32]). Conversely, in the hybrid-immunity model, the impacts of a booster
270 might be underestimated by using generalized booster efficacy and not accounting for the specific type of
271 hybrid immunity. Third, while we chose three countries with distinct parameterizations to calibrate these
272 models, fitting our models to data is challenging due to the difficulties of fitting individual-based models
273 and incorporating individual immune trajectories to compartmental models. While our results are therefore
274 more qualitative, they still match the patterns observed in incidence data.

275 When comparing the two models, the hybrid-immunity model might produce lower estimates of incidence
276 and deaths than the history-specific model for several reasons - for example, the inclusion of age-specific
277 contact rates (which are lower for older adults), reduced specificity of immune histories, and because im-
278 munity acquired during the current wave is likely to be stronger than pre-existing immunity, causing the
279 cross-protection achieved by natural infection to change gradually over time during the Omicron* wave for
280 the HSM but is fixed for the HIM. Deaths averted predicted by the HIM might also be lower than the HSM
281 because booster vaccination does not confer even short term sterilizing immunity and only reduces prob-
282 ability of infection and severe disease for future exposures. While we acknowledge the limitations of our
283 study, the outcomes of the two models presented here are consistent when evaluating the relative benefit of
284 booster formulation and we are confident that the qualitative findings of relative booster impacts are robust.

285 In summary, incorporating numerous sources of host heterogeneity across diverse settings and alternative
286 model structures has enabled us to quantify the relative impact of boosting compared to booster formu-
287 lation. We have demonstrated a consistent finding that in some places, the original generation of SARS-
288 CoV-2 monovalent boosters can still avert a similar number of deaths to the bivalent, without requiring the
289 acquisition of a new vaccine stock. These results have potential implications for future vaccine policy and
290 development.

291 **Methods**

292 **History-specific model (HSM)**

293 **Immune histories**

294 We projected previously reported data - neutralizing antibody titers from human sera which were stratified by
295 immune history [19, 20] - onto a scale from 0.05-0.95, with larger numbers representing higher protection
296 against SARS-CoV-2 (Figure 1A). Unvaccinated titers were those from individuals with no prior vaccine
297 doses, and vaccinated titers were those from individuals with 2 or more doses (fully vaccinated).

298 The base probabilities of (1) being infected after contact and (2) dying due to infections are scaled down
299 based on these wave- and history-specific parameters. This allowed us to parameterize single-infection
300 histories as well as hybrid histories for the WT, Delta, and Omicron waves. For individuals with 2 prior
301 infections, which was not accounted for in this data, we took an average of the ‘strain + vaccine’ serotypes
302 for each wave. For four or more immune history events, we assumed a protection parameter of 0.05 (95%).
303 For three history events (three infections or two infections + vaccine), we assumed the protection would

304 fall halfway between 2 events and 4+ events for each wave. Finally, we constructed an Omicron* wave by
305 drifting protection down by 0.10 for all groups, equal to the change in protection moving from the WT wave
306 to Delta. Individuals with ‘Omicron*’ or ‘Omicron* + vaccine’ histories are given protection equal to what
307 ‘Omicron’ and ‘Omicron + vaccine’ have during the Omicron wave.

308 **Model structure**

309 We implemented a stochastic, individual-based transmission model in Python. This model spans a period
310 of three years, through 4 discrete waves of SARS-CoV-2 variants: WT (beginning in March 2020), Delta,
311 Omicron, and a hypothetical Omicron lineage called Omicron* which we modeled to begin transmitting in
312 October 2022. Each wave has a distinct risk of infection given contact, estimated from household secondary
313 attack rates [7]. The simulated populations are grouped into children (0-20), adults (21-65), and elderly
314 (older than 65) whose proportions reflect the age structure of each country [33], with 50% being high SES
315 and 50% low SES. To capture relative waves sizes for each country, we implemented a stringency index with
316 a value for each wave (Table S1). We ran 500 replicates for each set of simulation parameters. Simulations
317 progress through a modified tau-leap algorithm [34]. General parameters are shown in Tables S3.

318 Country-specific, SES-stratified contact rates in this model are estimated from pre-pandemic contact data
319 for each country [35] combined with estimates of unequal mobility by SES during the pandemic [4] and the
320 tendency towards within-SES contact vs. across-SES [36, 37] (Table S5). Susceptible (S) individuals can
321 become exposed (E) through contact with an infectious individual (I). The probability of becoming exposed
322 given contact is stratified by variant-specific immune history. After exposure, they become infectious. The
323 probability that an infected individual will recover or die is stratified by age and SES [4], as well as variant-
324 specific immune history. While recently recovered (R), an individual does not have sterilizing immunity,
325 but rather a peak level of protection dictated by their immune history (Figure 1A), which comes from neu-
326 tralizing antibody titers in human sera [19, 20], and is order-agnostic. Recently recovered individuals have
327 a lower risk of infection and disease-related death than those in the susceptible class. Here, the protection
328 against infection is assumed to be 80% of the values shown in (Figure 1A) which apply to the risk of death
329 - reflecting evidence that in the early months after SARS-CoV-2 infection or vaccination, protection against
330 both severe disease and infection is high, but protection against infection is moderately lower [38]. After
331 recovery, individuals eventually wane into the susceptible class again, with a dampened immune history
332 protection parameter, and the amount of this dampening is dictated by their previous number of immune
333 exposures - with more exposure resulting in a lower degree of waning (Table S3). The incorporation of peak
334 (recently recovered class) and waned (susceptible class) protection as opposed to sterilizing immunity and
335 susceptibility reflects evidence that individuals are not fully protected against reinfection even when their
336 immune history is fresh [38]. This granularity in considering the peak and waned protection of an individual,
337 across immune histories, is a core strength of this model.

338 **Vaccination**

339 SES-stratified vaccination is implemented from day 320 (during the WT wave, around January 2021) until
340 the beginning of Omicron*, according to the true rates observed for each country [5] (Figure S3, Table S2).
341 Susceptible, exposed, and recently recovered individuals can be vaccinated - and if they are not already
342 recently recovered, they move to the recently recovered class. We stopped primary series vaccination at the
343 start of Omicron* reflecting that a small number of primary series doses were projected to be given during
344 Omicron* (Fig. S3), and to isolate the effect of boosting from interference by the primary series vaccines.

345 **Boosting**

346 Boosters function similarly to vaccination, but with faster timing and lower coverage (Figure S3, Table S8).
347 Booster rollout was assumed to be 10 weeks faster than primary series vaccination, to reflect possible im-
348 provements in infrastructure (Figure S3D, Table S8). We assumed that the coverage of monovalent boosters
349 in October 2023 represented a peak booster coverage level in the population [39]. Children and unvaccinated
350 individuals are not eligible to receive a booster, reflecting booster eligibility at the time of the study.

351 Data on booster efficacy by variant-specific immune history and formulation are limited. We therefore used
352 the neutralizing titer data [19, 20] to project booster-related changes in the level of protection against se-
353 vere disease, using responses to primary-series vaccination during the WT wave. Because Omicron* is a
354 hypothetical variant with no data on primary series vaccination responses, we assumed that the change in
355 protection from boosting would be the same as for the Omicron variant. Bivalent boosters were assumed to
356 confer the same numeric change as monovalent vaccines did during the WT wave. We considered monova-
357 lent boosters to have 40% of the efficacy of bivalent boosters against Omicron* infection based on estimates
358 of efficacy against severe infection [40]. Because we started boosting two months prior to Omicron*, there
359 was a two-month period when the bivalent and Omicron monovalent formulations were matched to the cur-
360 rently circulating variant, but the WT monovalent was not. To account for this, during the Omicron wave we
361 increased the Omicron monovalent efficacy by 10 percentage points (the change in protection for all groups
362 when moving from the Omicron wave to Omicron*) and bivalent protection by 5 percentage points (half of
363 what was applied for Omicron monovalent, because it contains both WT and Omicron) (Figure S6).

364 **Relative benefit**

365 Equation 1 quantifies the difference in booster benefit among different formulations, which we call the
366 relative benefit.

$$\text{Relative benefit (x,y)} = \frac{\text{Deaths averted under y vaccine formulation}}{\text{Deaths averted under x vaccine formulation}} \quad (1)$$

367 There are three key cases for the relative benefit:

- 368 (i) If (and only if) [Booster y deaths averted] < [Monovalent (WT) deaths averted], then the relative ben-
369 efit of booster y is less than 1.0.
- 370 (ii) If (and only if) [Booster y deaths averted] > [Monovalent (WT) deaths averted] and ([Booster y deaths averted] –
371 [Monovalent (WT) deaths averted]) < [Monovalent (WT) deaths averted], then the relative benefit is
372 between 1.0 and 2.0.
- 373 (iii) If (and only if) [Booster y deaths averted] > [Monovalent (WT) deaths averted] and ([Booster y deaths averted] –
374 [Monovalent (WT) deaths averted]) > [Monovalent (WT) deaths averted], then the relative benefit is
375 greater than 2.0.

376 In words, if the relative benefit is less than 1.0, then there is a net loss in the deaths averted when moving
377 from WT monovalent to Omicron monovalent or bivalent. If the new formulation averts more deaths than
378 monovalent (WT), but the gain moving from no-booster to a monovalent (WT) booster is larger than the
379 gain from monovalent (WT) to a new formulation, then the relative benefit is between 1.0 – 2.0. Finally, if
380 the new formulation both averts more deaths than monovalent (WT) and the gain moving from no-booster

381 to a monovalent (WT) booster is smaller than the gain from monovalent (WT) to a new formulation, then
382 the relative benefit is greater than 2.0.

383 **Hybrid-immunity model (HIM)**

384 **Model structure**

385 We also implemented a compartmental transmission model in R which extended a published COVID-19
386 transmission model [41] to account for vaccine-specific (none, vaccinated, vaccinated + boosted), natural
387 (0, 1+ infection), and hybrid immunity (combination). Our SEIR-like model includes six infection com-
388 partments: Susceptible S , Exposed E , Asymptomatic A , Symptomatic I , Recovered R , and Deceased D
389 (Figure S5). The model was also stratified by age (< 20 , $20 - 64$, and ≥ 65 years), socioeconomic status
390 (high vs. low), prior natural infection (no natural infection or one or more prior infection), and vaccine
391 status (unvaccinated, primary series, and boosted). Susceptible individuals become exposed through contact
392 with an infectious person (asymptomatic or asymptomatic), after which they enter a latent period (in the
393 exposed E class). After leaving the latent class, individuals develop either symptomatic or asymptomatic
394 infection. All asymptomatic individuals recover. Some symptomatic individuals recover, but some frac-
395 tion dies. Those in the low socioeconomic group have higher mortality rates [4], higher transmission rates
396 because of differences in pandemic mobility [4], and slower rates of vaccine rollout [5] than their higher
397 income counterparts. General parameters are shown in Table S3.

398 **Natural infection**

399 After recovery, individuals infected for the first time have sterilizing immunity for 300 days (10 months),
400 after which point they enter the susceptible class for individuals with prior infection (S_2). Our main sim-
401 ulations assume that 50% of those who have been infected previously have waned as of October 2022,
402 consistent with most natural immunity having been acquired during the omicron wave, but we consider an
403 alternative where 75% have waned as a sensitivity analysis. Individuals who have been previously infected
404 have a lower rate of infection ($1 - 0.8cp$) and mortality ($1 - cp$), which is influenced by the level of cross
405 protection (cp) between the prior infecting strains (based on the population-averaged immune history) and
406 the currently circulating strain. Upon re-infection, previously infected individuals can follow the same steps
407 as for the compartments in the base model. We only model two levels of infection, assuming that infectivity
408 and severity are similar for secondary and higher infections. The level of pre-existing immunity and cross
409 protection at the start of the Omicron* wave was estimated for each country based on the population immune
410 history profiles from the history-specific model (Table S9).

411 **Vaccination**

412 *Primary series vaccination.* Vaccination was implemented by adding additional compartments for vacci-
413 nated/vaccinated and boosted individuals, which mirror the compartments in the base model: S_V , E_V , A_V ,
414 I_V , R_V , and D_V for vaccination. We assumed that everyone who was planning to receive their primary
415 vaccine series had already done so as of October 2022, so only booster vaccines were included in our main
416 model simulations, matching the HSM. Baseline vaccine prevalence in October 2022 was set in the same
417 was as the HSM, following published data from [5].

418 Vaccine efficacy for the primary series was assumed to reduce the risk of mortality by 70%, consistent with
419 data on Astra-Zeneca protection after 6 months [42–45]. While primary series vaccination for Astra-Zeneca

420 can reduce risk of infection by about 50%, these benefits are only present shortly after vaccination [42–45].
421 Given that the populations included in our model completed their vaccine campaigns earlier and current
422 rollout rates are low, we do not model any protection against infection for the primary vaccination class.

423 *Booster vaccination.* To capture the potential for booster vaccination, we added additional compartments
424 (S_B , E_B , A_B , I_B , R_B , and D_B). For simplicity, we assume that individuals in the S , E , or R classes
425 can be vaccinated but individuals in the other compartments will not be. To reflect the fact that coverage
426 of vaccine boosters was low in LMICs in October 2022, when HIM simulations began, only one boosted
427 class was used and its efficacy was varied to reflect the potential benefit of variant specific boosters. Booster
428 vaccination moves vaccinated individuals to the corresponding booster class, but does not confer specific
429 temporary immunity (unlike the HSM). In other words, S_V individuals move to the S_B class, not the R_B
430 class. Similar to the HSM, we only model adult boosting. We implemented vaccination using dynamic daily
431 rates using the same approach as the history-specific model (Table S8), where daily doses were administered
432 until coverage saturates at its peak level. We considered an optimistic roll out as our default scenario, where
433 the halfway week of the rollout curve was sped up by 10 weeks compared to primary series vaccination, but
434 also considered a conservative rollout as a sensitivity analysis where the speed of boosting matches primary
435 series vaccination (Table S2).

436 **Hybrid immunity**

437 We also explicitly accounted for joint natural immunity and vaccine-derived immunity—individuals who
438 have both exposures are tracked in a vaccinated and infected classes (S_{V2} , E_{V2} , A_{V2} , I_{V2} , R_{V2} , and D_{V2})
439 or vaccinated and boosted classes (S_{B2} , E_{B2} , A_{B2} , I_{B2} , R_{B2} , and D_{B2}) and their protection from both
440 exposures is modeled as multiplicative. For example, bivalent vaccination reduces risk of infection by 74%.
441 In Malaysia, cross protection from prior infection was estimated at 72.8%. Thus, an individual with both
442 exposures has an infection risk of $(1 - 0.74) \times (1 - 0.73) \times \beta$ or a combined reduction in infection risk of
443 93%. We do not differentiate between the order of vaccination and natural infection in the hybrid immunity
444 model.

445 Booster vaccination can enhance protection against both infection (VE_i) and severe disease (VE_h). We
446 use scenarios consistent with the individual-based model bivalent booster efficacy ($VE_i = 0.74$, $VE_h =$
447 0.925) and monovalent booster efficacy ($VE_i = 0.657$, $VE_h = 0.5256$) in the main analysis. While this
448 yields a lower efficacy against severe disease specifically for the monovalent booster (VE_h) compared with
449 primary series vaccination, the total protection against severe disease is higher (84%) due to the inclusion of
450 protection against infection.

451 **Acknowledgements**

452 This work was funded by the World Health Organization. The authors would like to thank the Biocluster at
453 the Carl R. Woese Institute for Genomic Biology, University of Illinois Urbana-Champaign, for providing
454 access to the computing resources.

455 **Competing interests**

456 The authors declare that they have no competing interests.

457 **Data and materials availability**

458 All codes and data necessary to evaluate the conclusions of the paper and reproduce the figures in the main
459 text will be made available upon publication.

460 **References**

- 461 [1] Ke R, Martinez PP, Smith RL, Gibson LL, Mirza A, Conte M, et al. Daily longitudinal sampling
462 of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. *Nature microbiology*.
463 2022;7(5):640-52.
- 464 [2] Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM. Superspreading and the effect of individual vari-
465 ation on disease emergence. *Nature*. 2005;438(7066):355-9.
- 466 [3] Huang J, Kwan MP, Kan Z. The superspreading places of COVID-19 and the associated built-
467 environment and socio-demographic features: A study using a spatial network framework and
468 individual-level activity data. *Health & Place*. 2021;72:102694.
- 469 [4] Mena GE, Martinez PP, Mahmud AS, Marquet PA, Buckee CO, Santillana M. Socioeco-
470 nomic status determines COVID-19 incidence and related mortality in Santiago, Chile. *Science*.
471 2021;372(6545):eabg5298.
- 472 [5] Larsen SL, Shin I, Joseph J, West H, Anorga R, Mena GE, et al. Quantifying the impact of
473 SARS-CoV-2 temporal vaccination trends and disparities on disease control. *Science Advances*.
474 2023;9(31):eadh9920.
- 475 [6] Riou J, Panczak R, Althaus CL, Junker C, Perisa D, Schneider K, et al. Socioeconomic position and
476 the COVID-19 care cascade from testing to mortality in Switzerland: a population-based analysis. *The*
477 *Lancet Public Health*. 2021;6(9):e683-91.
- 478 [7] Madewell ZJ, Yang Y, Longini IM, Halloran ME, Dean NE. Household secondary attack rates of
479 SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis.
480 *JAMA network open*. 2022;5(4):e229317.
- 481 [8] Suryawanshi R, Ott M. SARS-CoV-2 hybrid immunity: silver bullet or silver lining? *Nature Reviews*
482 *Immunology*. 2022;22(10):591-2.
- 483 [9] Tan CW, Chia WN, Zhu F, Young BE, Chantasrisawad N, Hwa SH, et al. SARS-CoV-2 Omicron
484 variant emerged under immune selection. *Nature Microbiology*. 2022;7:1756-61.
- 485 [10] Röltgen K, Nielsen SC, Silva O, Younes SF, Zaslavsky M, Costales C, et al. Immune imprinting,
486 breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and
487 vaccination. *Cell*. 2022;185(6):1025-40.
- 488 [11] Wheatley AK, Fox A, Tan HX, Juno JA, Davenport MP, Subbarao K, et al. Immune imprinting and
489 SARS-CoV-2 vaccine design. *Trends in Immunology*. 2021;42(11):956-9.
- 490 [12] Gostic KM, Ambrose M, Worobey M, Lloyd-Smith JO. Potent protection against H5N1 and H7N9
491 influenza via childhood hemagglutinin imprinting. *Science*. 2016;354(6313):722-6.

- 492 [13] Oidtman RJ, Arevalo P, Bi Q, McGough L, Russo CJ, Cruz DV, et al. Influenza immune escape under
493 heterogeneous host immune histories. *Trends in Microbiology*. 2021;29(12):1072-82.
- 494 [14] Lv H, So RT, Teo QW, Yuan M, Liu H, Lee CCD, et al. Neutralizing Antibody Response to Sarbe-
495 covirus Is Delayed in Sequential Heterologous Immunization. *Viruses*. 2022;14(7):1382.
- 496 [15] Lin CY, Wolf J, Brice DC, Sun Y, Locke M, Cherry S, et al. Pre-existing humoral immunity to human
497 common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response. *Cell*
498 *host & microbe*. 2022;30(1):83-96.
- 499 [16] Zelner J, Naraharisetti R, Zelner S. Invited commentary: to make long-term gains against infection
500 inequity, infectious disease epidemiology needs to develop a more sociological imagination. *American*
501 *Journal of Epidemiology*. 2023:kwad044.
- 502 [17] Tizzoni M, Nsoesie EO, Gauvin L, Karsai M, Perra N, Bansal S. Addressing the socioeconomic divide
503 in computational modeling for infectious diseases. *Nature Communications*. 2022;13(1):2897.
- 504 [18] Heesterbeek H, Anderson RM, Andreasen V, Bansal S, De Angelis D, Dye C, et al. Modeling infectious
505 disease dynamics in the complex landscape of global health. *Science*. 2015;347(6227):aaa4339.
- 506 [19] Manali M, Bissett LA, Amat JA, Logan N, Scott S, Hughes EC, et al. SARS-CoV-2 evolution and
507 patient immunological history shape the breadth and potency of antibody-mediated immunity. *The*
508 *Journal of infectious diseases*. 2023;227(1):40-9.
- 509 [20] Suryawanshi RK, Chen IP, Ma T, Syed AM, Brazer N, Saldhi P, et al. Limited cross-variant immunity
510 from SARS-CoV-2 Omicron without vaccination. *Nature*. 2022;607(7918):351-5.
- 511 [21] WHO Coronavirus (COVID-19) Dashboard;. <https://covid19.who.int/>.
- 512 [22] Jung J, Kim JY, Park H, Park S, Lim JS, Lim SY, et al. Transmission and Infectious SARS-
513 CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals. *JAMA Network Open*.
514 2022;5(5):e2213606-6.
- 515 [23] Burki TK. Omicron variant and booster COVID-19 vaccines. *Lancet Respiratory Medicine*.
516 2022;10(2).
- 517 [24] Bergeri I, Whelan MG, Ware H, Subissi L, Nardone A, Lewis HC, et al. Global SARS-CoV-2 sero-
518 prevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized
519 population-based studies. *PLoS medicine*. 2022;19(11):e1004107.
- 520 [25] Jayaraj VJ, Ng CW, Bulgiba A, Appannan MR, Rampal S. Estimating the infection burden of COVID-
521 19 in Malaysia. *PLOS Neglected Tropical Diseases*. 2022;16(11):e0010887.
- 522 [26] Van V. A new evolutionary law. 1973.
- 523 [27] Morris DH, Gostic KM, Pompei S, Bedford T, Łuksza M, Neher RA, et al. Predictive modeling of
524 influenza shows the promise of applied evolutionary biology. *Trends in microbiology*. 2018;26(2):102-
525 18.
- 526 [28] Agor JK, Özaltın OY. Models for predicting the evolution of influenza to inform vaccine strain selec-
527 tion. *Human vaccines & immunotherapeutics*. 2018;14(3):678-83.

- 528 [29] Cankat S, Demael M, Swadling L. In search of a pan-coronavirus vaccine: next-generation vaccine
529 design and immune mechanisms. *Cellular & Molecular Immunology*. 2023;21:103-18.
- 530 [30] Tan CW, Valkenburg SA, Poon LL, Wang LF. Broad-spectrum pan-genus and pan-family virus vac-
531 cines. *Cell Host & Microbe*. 2023;31(6):902-16.
- 532 [31] Khoury DS, Schlub TE, Cromer D, Steain M, Fong Y, Gilbert PB, et al. Correlates of protection,
533 thresholds of protection, and immunobridging among persons with SARS-CoV-2 infection. *Emerging
534 Infectious Diseases*. 2023;29(2):381.
- 535 [32] Dimeglio C, Miguères M, Bouzid N, Chapuy-Regaud S, Gernigon C, Da-Silva I, et al. Antibody titers
536 and protection against Omicron (BA. 1 and BA. 2) SARS-CoV-2 infection. *Vaccines*. 2022;10(9):1548.
- 537 [33] Population estimates and projections for 227 countries and areas.; 2022. [https://www.census.
538 gov/data-tools/demo/idb/#/pop?COUNTRY_YEAR=2022&COUNTRY_YR_ANIM=
539 2022&FIPS_SINGLE=EC&FIPS=EC&popPages=BYAGE&POP_YEARS=2022&menu=
540 popViz](https://www.census.gov/data-tools/demo/idb/#/pop?COUNTRY_YEAR=2022&COUNTRY_YR_ANIM=2022&FIPS_SINGLE=EC&FIPS=EC&popPages=BYAGE&POP_YEARS=2022&menu=popViz).
- 541 [34] Cao Y, Gillespie DT, Petzold LR. Avoiding negative populations in explicit Poisson tau-leaping. *The
542 Journal of chemical physics*. 2005;123(5):054104.
- 543 [35] Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using contact surveys
544 and demographic data. *PLOS Computational Biology*. 2017;13:e1005697.
- 545 [36] Yechezkel M, Weiss A, Rejwan I, Shahmoon E, Ben-Gal S, Yamin D. Human mobility and poverty as
546 key drivers of COVID-19 transmission and control. *BMC public health*. 2021;21(1):1-13.
- 547 [37] Bokányi E, Juhász S, Karsai M, Lengyel B. Universal patterns of long-distance commuting and social
548 assortativity in cities. *Scientific reports*. 2021;11(1):1-10.
- 549 [38] Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al. Protective effectiveness of previous SARS-
550 CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic
551 review and meta-regression. *The Lancet Infectious Diseases*. 2023.
- 552 [39] in Data O. Coronavirus (COVID-19) Vaccinations;. Available from: [https://
553 ourworldindata.org/covid-vaccinations](https://ourworldindata.org/covid-vaccinations).
- 554 [40] Lin DY, Xu Y, Gu Y, Zeng D, Wheeler B, Young H, et al. Effectiveness of bivalent boosters against
555 severe omicron infection. *New England Journal of Medicine*. 2023;388(8):764-6.
- 556 [41] Kraay ANM, Gallagher ME, Ge Y, Han P, Baker JM, Koelle K, et al. The role of booster vaccination
557 and ongoing viral evolution in seasonal circulation of SARS-CoV-2. *Journal of the Royal Society
558 Interface*. 2022;19:20220477.
- 559 [42] Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effective-
560 ness against the Omicron (B.1.1.529) Variant. *New England Journal of Medicine*. 2022;386(16):1532-
561 46.
- 562 [43] Zeneca A. COVID-19 Vaccine AstraZeneca Real-World Evidence Summary;. Available
563 from: [https://www.astrazeneca.com/content/dam/az/covid-19/media/
564 factsheets/COVID-19_Vaccine_AstraZeneca_Real-World_Evidence_
565 Summary.pdf](https://www.astrazeneca.com/content/dam/az/covid-19/media/factsheets/COVID-19_Vaccine_AstraZeneca_Real-World_Evidence_Summary.pdf).

- 566 [44] Zeneca A. Boosting with AstraZeneca's vaccine provides high protection against
567 Omicron, equivalent to mRNA COVID-19 vaccines;. Available from: [https://www.astrazeneca.com/country-sites/thailand/press-releases/
568 boosting-with-astrazenecas-vaccine-provides-high-protection-against-omicron-
569 html](https://www.astrazeneca.com/country-sites/thailand/press-releases/boosting-with-astrazenecas-vaccine-provides-high-protection-against-omicron.html).
570
- 571 [45] Solante R, Alvarez-Moreno C, Burhan E, Chariyalertsak S, Chiu NC, Hwang KP, et al. Expert Review
572 of Global Real-World Data on COVID-19 Vaccine Booster Effectiveness Safety During the Omicron-
573 dominant Phase of the Pandemic. *Research Square*. 2022;22(1):1-16.
- 574 [46] Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, et al. Coronavirus Pandemic
575 (COVID-19). *Our World in Data*. 2020. <https://ourworldindata.org/coronavirus>.
- 576 [47] Murhekar MV, Bhatnagar T, Selvaraju S, Saravanakumar V, Thangaraj JWV, Shah N, et al. SARS-CoV-
577 2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide
578 household serosurvey. *Lancet Global Health*. 2021;59:E257-66.
- 579 [48] Megasari NLA, Utsumi T, Yamani LN, Juniastuti, Gunawan E, Furukawa K, et al. Seroepidemiological
580 study of SARS-CoV-2 infection in East Java, Indonesia. *Plos one*. 2021;16(5):e0251234.
- 581 [49] Acurio-Páez D, Vega B, Orellana D, Charry R, Gómez A, Obimpeh M, et al. Seroprevalence of
582 SARS-CoV-2 Infection and Adherence to Preventive Measures in Cuenca, Ecuador, October 2020, a
583 Cross-Sectional Study. *Int J Environ Res Public Health*. 2021;18:4657.
- 584 [50] Wu Y, Kang L, Gao Z, Liu J, Liu M, Liang W. Incubation Period of COVID-19 Caused by Unique
585 SARS-CoV-2 Strains: A Systematic Review and Meta-analysis. *JAMA Network Open*. 2022;5(8).
- 586 [51] Jung CY, Park H, Kim DW, Choi YJ, Kim SW, Chang TI. Clinical characteristics of asymptomatic
587 patients with COVID-19: a nationwide cohort study in South Korea. *International Journal of Infectious
588 Diseases*. 2020;99:266-8.
- 589 [52] CDC. COVID-19 Pandemic Planning Scenarios; 2020. Available from: [https://www.cdc.gov/
590 coronavirus/2019-ncov/hcp/planning-scenarios.html#box1](https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html#box1).
- 591 [53] Subramanian R, He Q, Pascual M. Quantifying asymptomatic infection and transmission of COVID-
592 19 in New York City using observed cases, serology, and testing capacity. *Proceedings of the National
593 Academy of Sciences*. 2021;118(9):e2019716118.
- 594 [54] Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of
595 SARS-CoV-2 through the postpandemic period. *Science*. 2020;368(6493):860-8.
- 596 [55] Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Grifoni CEF, et al. Immunological memory to SARS-
597 CoV-2 assessed for up to 8 months after infection. *Science*. 2021;371(6529).
- 598 [56] Altawalrah H. Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination.
599 *Vaccines (Basel)*. 2021;9(8).